Advanced search
Publication Cover
Biomarkers in Medicine Volume 3, 2009 - Issue 4
Submit an article Journal homepage
286
Views
0
CrossRef citations to date
0
Altmetric
Review

Molecular Biomarkers in Stroke Diagnosis and Prognosis

Matthew B Maas1 175 Cambridge Street, Suite 300,Boston,MA 02114,USA. ;2 Department of Neurology,Massachusetts General Hospital,Harvard Medical School,MA,USACorrespondence[email protected]
View further author information
&
Karen L Furie2 Department of Neurology,Massachusetts General Hospital,Harvard Medical School,MA,USAView further author information
Pages 363-383 | Published online: 06 Aug 2009

Bibliography

  • Rosamond W , FlegalK, FurieKet al.: Heart disease and stroke statistics – 2008 update: a report from the american heart association statistics committee and stroke statistics subcommittee.Circulation117(4), e25–e146 (2008).
  • Goldstein LB , AdamsR, AlbertsMJet al.: Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline.Stroke37(6), 1583–1633 (2006).
  • Sacco RL , AdamsR, AlbersGet al.: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.Stroke37(2), 577–617 (2006).
  • Adams RJ , AlbersG, AlbertsMJet al.: Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.Stroke39(5), 1647–1652 (2008).
  • Alpert JS , ThygesenK, AntmanE, BassandJP: Myocardial infarction redefined – a consensus document of the joint european society of Cardiology/American college of cardiology committee for the redefinition of myocardial infarction.J. Am. Coll. Cardiol.36(3), 959–969 (2000).
  • Dirnagl U , IadecolaC, MoskowitzMA: Pathobiology of ischaemic stroke: an integrated view.Trends Neurosci.22(9), 391–397 (1999).
  • Lee JM , ZipfelGJ, ChoiDW: The changing landscape of ischaemic brain injury mechanisms.Nature399(6738), A7–A14 (1999).
  • Schaller B , GrafR: Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy.J. Cereb. Blood Flow Metab.24(4), 351–371 (2004).
  • Doyle KP , SimonRP, Stenzel-PooreMP: Mechanisms of ischemic brain damage.Neuropharmacology55(3), 310–318 (2008).
  • Hallenbeck JM : The many faces of tumor necrosis factor in stroke.Nat. Med.8(12), 1363–1368 (2002).
  • Mun-Bryce S , RosenbergGA: Matrix metalloproteinases in cerebrovascular disease.J. Cereb. Blood Flow Metab.18(11), 1163–1172 (1998).
  • Rose JC , MayerSA: Optimizing blood pressure in neurological emergencies.Neurocrit. Care1(3), 287–299 (2004).
  • Adhami F , LiaoG, MorozovYMet al.: Cerebral ischemia-hypoxia induces intravascular coagulation and autophagy.Am. J. Pathol.169(2), 566–583 (2006).
  • Kögel D , PetersM, KönigHGet al.: S100B potently activates p65/c-rel transcriptional complexes in hippocampal neurons: clinical implications for the role of S100B in excitotoxic brain injury.Neuroscience127(4), 913–920 (2004).
  • Rothermundt M , PetersM, PrehnJH, AroltV: S100B in brain damage and neurodegeneration.Microsc. Res. Tech.60(6), 614–632 (2003).
  • Foerch C , OttoB, SingerOCet al.: Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion.Stroke35(9), 2160–2164 (2004).
  • Persson L , HardemarkH, EdnerG, RonneE, Mendel-HartvigI, PahlmanS: S-100 protein in cerebrospinal fluid of patients with subarachnoid haemorrhage: a potential marker of brain damage.Acta Neurochir. (Wien)93(3–4), 116–122 (1988).
  • Jauch EC , LindsellC, BroderickJet al.: Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator stroke study.Stroke37(10), 2508–2513 (2006).
  • Foerch C , WunderlichMT, DvorakFet al.: Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke.Stroke38(9), 2491–2495 (2007).
  • Delgado P , Alvarez-SabínJ, SantamarinaEet al.: Plasma S100B level after acute spontaneous intracerebral hemorrhage.Stroke37(11), 2837–2839 (2006).
  • Hill MD , JackowskiG, BayerN, LawrenceM, JaeschkeR: Biochemical markers in acute ischemic stroke.CMAJ162(8), 1139–1140 (2000).
  • Anderson RE , HanssonLO, NilssonO, Dijlai-MerzougR, SettergrenG: High serum S100B levels for trauma patients without head injuries.Neurosurgery48(6), 1255–1258; discussion 1258–1260 (2001).
  • Fazio V , BhudiaSK, MarchiN, AumayrB, JanigroD: Peripheral detection of S100β during cardiothoracic surgery: what are we really measuring?Ann. Thorac. Surg.78(1), 46–43 (2004).
  • Anderson RE , HanssonLO, NilssonO, LiskaJ, SettergrenG, VaageJ: Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources.Ann. Thorac. Surg.71(5), 1512–1517 (2001).
  • Rainer TH , WongKS, LamW, LamNY, GrahamCA, LoYM: Comparison of plasma β-globin DNA and S-100 protein concentrations in acute stroke.Clin. Chim. Acta376(1–2), 190–196 (2007).
  • Marchi N , CavagliaM, FazioV, BhudiaS, HalleneK, JanigroD: Peripheral markers of blood-brain barrier damage.Clin. Chim. Acta342(1–2), 1–12 (2004).
  • Vogelbaum MA , MasarykT, MazzonePet al.: S100b as a predictor of brain metastases: brain versus cerebrovascular damage.Cancer104(4), 817–824 (2005).
  • Pelinka LE , KroepflA, SchmidhammerRet al.: Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma.J. Trauma57(5), 1006-1012 (2004).
  • Aurell A , RosengrenLE, KarlssonB, OlssonJE, ZbornikovaV, HaglidKG: Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction.Stroke22(10), 1254–1258 (1991).
  • Herrmann M , VosP, WunderlichMT, de BruijnC, LamersKJ: Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke31(11), 2670–2677 (2000).
  • Foerch C , CurdtI, YanBet al.: Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke.J. Neurol. Neurosurg. Psychiatr.77(2), 181–184 (2006).
  • Cohen SR , BrooksBR, HerndonRM, McKhannGM: A diagnostic index of active demyelination: myelin basic protein in cerebrospinal fluid.Ann. Neurol.8(1), 25–31 (1980).
  • Matias-Guiu J , Martinez-VazquezJ, RuibalA, ColomerR, BoadaM, CodinaA: Myelin basic protein and creatine kinase BB isoenzyme as CSF markers of intracranial tumors and stroke.Acta Neurol. Scand.73(5), 461–465 (1986).
  • Veerkamp JH , ZimmermanAW: Fatty acid-binding proteins of nervous tissue.J. Mol. Neurosci.16(2–3), 133–137 (2001).
  • Wunderlich MT , HanhoffT, GoertlerMet al.: Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke.J. Neurol.252(6), 718–724 (2005).
  • Pelsers MM , HanhoffT, Van dV et al.: Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin. Chem.50(9), 1568–1575 (2004).
  • Liao J , ChanCP, CheungYCet al.: Human heart-type fatty acid-binding protein for on-site diagnosis of early acute myocardial infarction.Int. J. Cardiol.133(3), 420–423 (2009).
  • Zimmerman AW , van MoerkerkH, VeerkampJH: Ligand specificity and conformational stability of human fatty acid-binding proteins. Int. J. Biochem. Cell Biol.33(9), 865–876 (2001).
  • Zimmermann-Ivol CG , BurkhardPR, Le Floch-RohrJ, AllardL, HochstrasserDF, SanchezJC: Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol. Cell. Proteomics3(1), 66–72 (2004).
  • Persson L , HardemarkHG, GustafssonJet al.: S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system.Stroke18(5), 911–918 (1987).
  • Anand N , SteadLG: Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review.Cerebrovasc. Dis.20(4), 213–219 (2005).
  • Fassbender K , SchmidtR, SchreinerAet al.: Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke.J. Neurol. Sci.148(1), 101–105 (1997).
  • Casmiro M , MaitanS, De Pasquale F et al.: Cerebrospinal fluid and serum neuron-specific enolase concentrations in a normal population. Eur. J. Neurol.12(5), 369–374 (2005).
  • Wunderlich MT , LinsH, SkalejM, WalleschCW, GoertlerM: Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke.Clin. Neurol. Neurosurg.108(6), 558–563 (2006).
  • Stevens H , JakobsC, de JagerA, CunninghamRT, KorfJ: Neurone-specific enolase and N-acetyl-aspartate as potential peripheral markers of ischaemic stroke. Eur. J. Clin. Invest.29(1), 6–11 (1999).
  • Williams DR : Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau.Intern. Med. J.36(10), 652–660 (2006).
  • Hesse C , RosengrenL, VanmechelenEet al.: Cerebrospinal fluid markers for Alzheimer‘s disease evaluated after acute ischemic stroke.J. Alzheimers Dis.2(3–4), 199–206 (2000).
  • Hesse C , RosengrenL, AndreasenNet al.: Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.Neurosci. Lett.297(3), 187–190 (2001).
  • Lidstrom AM , HesseC, RosengrenL, FredmanP, DavidssonP, BlennowK: Normal levels of clusterin in cerebrospinal fluid in Alzheimer‘s disease, and no change after acute ischemic stroke.J. Alzheimers Dis.3(5), 435–442 (2001).
  • Rosengren LE , KarlssonJE, KarlssonJO, PerssonLI, Wikkels⊘C: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF.J. Neurochem.67(5), 2013–2018 (1996).
  • Baslow MH : Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review.Neurochem. Int.40(4), 295–300 (2002).
  • Petroff OA , GrahamGD, BlamireAMet al.: Spectroscopic imaging of stroke in humans: histopathology correlates of spectral changes.Neurology42(7), 1349–1354 (1992).
  • Sager TN , LaursenH, HansenAJ: Changes in N-acetyl-aspartate content during focal and global brain ischemia of the rat.J. Cereb. Blood Flow Metab.15(4), 639–646 (1995).
  • Sager TN , HansenAJ, LaursenH: Correlation between N-acetylaspartate levels and histopathologic changes in cortical infarcts of mice after middle cerebral artery occlusion.J. Cereb. Blood Flow Metab.20(5), 780–788 (2000).
  • Pereira AC , SaundersDE, DoyleVLet al.: Measurement of initial N-acetyl aspartate concentration by magnetic resonance spectroscopy and initial infarct volume by MRI predicts outcome in patients with middle cerebral artery territory infarction.Stroke30(8), 1577–1582 (1999).
  • Saunders DE : MR spectroscopy in stroke.Br. Med. Bull.56(2), 334–345 (2000).
  • Walker PM , Ben SalemD, LalandeA, GiroudM, BrunotteF: Time course of NAA T2 and ADC(w) in ischaemic stroke patients: 1H MRS imaging and diffusion-weighted MRI. J. Neurol. Sci.220(1–2), 23–28 (2004).
  • Elting JW , SulterGA, LangedijkM, LuijckxGJ, TeelkenAW, De KeyserJ: N-acetylaspartate: serum marker of reperfusion in ischemic stroke. J. Stroke Cerebrovasc. Dis.13(6), 254–258 (2004).
  • Dambinova SA , KhounteevGA, SkorometsAA: Multiple panel of biomarkers for TIA/stroke evaluation.Stroke33(5), 1181–1182 (2002).
  • Dambinova SA , KhounteevGA, IzykenovaGA, ZavolokovIG, IlyukhinaAY, SkorometsAA: Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke.Clin. Chem.49(10), 1752–1762 (2003).
  • Allard L , LescuyerP, BurgessJet al.: ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke.Proteomics4(8), 2242–2251 (2004).
  • Dai FF , ZhangY, KangYet al.: The neuronal Ca2+ sensor protein visinin-like protein-1 is expressed in pancreatic islets and regulates insulin secretion.J. Biol. Chem.281(31), 21942–21953 (2006).
  • Laterza OF , ModurVR, CrimminsDLet al.: Identification of novel brain biomarkers.Clin. Chem.52(9), 1713–1721 (2006).
  • Tran ND , WongVL, SchreiberSS, BreadyJV, FisherM: Regulation of brain capillary endothelial thrombomodulin mRNA expression.Stroke27(12), 2304–2301 (1996).
  • Olivot JM , LabreucheJ, De Broucker T et al.: Thrombomodulin gene polymorphisms in brain infarction and mortality after stroke. J. Neurol.255(4), 514–519 (2008).
  • Olivot JM , LabreucheJ, AiachM, AmarencoP, InvestigatorsG: Soluble thrombomodulin and brain infarction: case–control and prospective study.Stroke35(8), 1946–1951 (2004).
  • Nomura E , KohriyamaT, KozukaK, KajikawaH, NakamuraS, MatsumotoM: Significance of serum soluble thrombomodulin level in acute cerebral infarction.Eur. J. Neurol.11(5), 329–334 (2004).
  • Kozuka K , KohriyamaT, NomuraE, IkedaJ, KajikawaH, NakamuraS: Endothelial markers and adhesion molecules in acute ischemic stroke – sequential change and differences in stroke subtype.Atherosclerosis161(1), 161–168 (2002).
  • Bushnell C , SiddiqiZ, MorgenlanderJ, GoldsteinL: Use of specialized coagulation testing in the evaluation of patients with acute ischemic stroke.Neurology56(5), 624–627 (2001).
  • Bushnell C , SiddiqiZ, GoldsteinL: Improving patient selection for coagulopathy testing in the setting of acute ischemic stroke.Neurology57(7), 1333–1335 (2001).
  • Levine SR , BreyRL, TilleyBCet al.: Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.JAMA291(5), 576–584 (2004).
  • Tapson VF : Acute pulmonary embolism.N. Engl. J. Med.358(10), 1037–1052 (2008).
  • Beamer NB , CoullBM, ClarkWM, HazelJS, SilbergerJR: Interleukin-6 and interleukin-1 receptor antagonist in acute stroke.Ann. Neurol.37(6), 800–805 (1995).
  • Di Napoli M , PapaF, BocolaV: Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke.Stroke32(1), 133–138 (2001).
  • Di Napoli M , SinghP: Is plasma fibrinogen useful in evaluating ischemic stroke patients? why, how, and when.Stroke40(5), 1549–1552 (2009).
  • Barber M , LanghorneP, RumleyA, LoweGD, StottDJ: Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression.Stroke35(6), 1421–1425 (2004).
  • Barber M , LanghorneP, RumleyA, LoweGD, StottDJ: D-dimer predicts early clinical progression in ischemic stroke: confirmation using routine clinical assays.Stroke37(4), 1113–1115 (2006).
  • Delgado P , Alvarez-SabínJ, AbilleiraSet al.: Plasma D-dimer predicts poor outcome after acute intracerebral hemorrhage.Neurology67(1), 94–98 (2006).
  • Welsh P , BarberM, LanghorneP, RumleyA, LoweGD, StottDJ: Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke.Cerebrovasc. Dis.27(3), 247–253 (2009).
  • Feinberg WM , EricksonLP, BruckD, KittelsonJ: Hemostatic markers in acute ischemic stroke. association with stroke type, severity, and outcome.Stroke27(8), 1296–1300 (1996).
  • Carter AM , CattoAJ, MansfieldMW, BamfordJM, GrantPJ: Predictive variables for mortality after acute ischemic stroke.Stroke38(6), 1873–1880 (2007).
  • Fon EA , MackeyA, CôtéRet al.: Hemostatic markers in acute transient ischemic attacks.Stroke25(2), 282–286 (1994).
  • Carrieri P , OreficeG, IndacoA: No effect of acetylsalicylic acid on B-thromboglobulin and platelet factor 4 plasma levels in patients with transient ischaemic attacks.Stroke17(6), 1153–1155 (1986).
  • Shah AB , BeamerN, CoullBM: Enhanced in vivo platelet activation in subtypes of ischemic stroke.Stroke16(4), 643–647 (1985).
  • Kang DW , YooSH, ChunSet al.: Inflammatory and hemostatic biomarkers associated with early recurrent ischemic lesions in acute ischemic stroke.Stroke40(5), 1653–165 8 (2009).
  • Haapaniemi E , TatlisumakT: Is D-dimer helpful in evaluating stroke patients? A systematic review.Acta Neurol. Scand.119(3), 141–150 (2009).
  • Ay H , ArsavaEM, GungorLet al.: Admission international normalized ratio and acute infarct volume in ischemic stroke.Ann. Neurol.64(5), 499–506 (2008).
  • Montaner J , RibóM, MonasterioJ, MolinaCA, Alvarez-SabínJ: Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke.Stroke34(4), 1038–1040 (2003).
  • Arenillas JF , Alvarez-SabínJ, MolinaCAet al.: Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis.Stroke39(5), 1456–1463 (2008).
  • Ribó M , MontanerJ, MolinaCA, ArenillasJF, SantamarinaE, Alvarez-SabínJ: Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator.Thromb. Haemost.91(6), 1146–1151 (2004).
  • Ribó M , MontanerJ, MolinaCAet al.: Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.Stroke35(9), 2123–2127 (2004).
  • Fernandez-Cadenas I , Alvarez-SabínJ, RiboMet al.: Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.J. Thromb. Haemost.5(9), 1862–1868 (2007).
  • Emsley HC , SmithCJ, GavinCMet al.: Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production.BMC Neurol.7, 5 (2007).
  • Kim JS , YoonSS, KimYH, RyuJS: Serial measurement of interleukin-6, transforming growth factor-β, and S-100 protein in patients with acute stroke.Stroke27(9), 1553–1557 (1996).
  • Montaner J , Alvarez-SabínJ, BarberáGet al.: Correlation between the expression of proinflammatory cytokines and matrix metalloproteinases in the acute phase of an ischemic stroke.Rev. Neurol.33(2), 115–118 (2001).
  • Dziedzic T , BartusS, KlimkowiczA, MotylM, SlowikA, SzczudlikA: Intracerebral hemorrhage triggers interleukin-6 and interleukin-10 release in blood.Stroke33(9), 2334–2335 (2002).
  • Montaner J , RoviraA, MolinaCAet al.: Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke.J. Cereb. Blood Flow Metab.23(12), 1403–1407 (2003).
  • Montaner J , ChacónP, KrupinskiJet al.: Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial.Eur. J. Neurol.15(1), 82–90 (2008).
  • Emsley HC , SmithCJ, GavinCMet al.: An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis.J. Neuroimmunol.139(1–2), 93–101 (2003).
  • Sotgiu S , ZandaB, MarchettiBet al.: Inflammatory biomarkers in blood of patients with acute brain ischemia.Eur. J. Neurol.13(5), 505–513 (2006).
  • Sotgiu S , BaroneR, ZandaBet al.: Chitotriosidase in patients with acute ischemic stroke.Eur. Neurol.54(3), 149–153 (2005).
  • Vila N , CastilloJ, DávalosA, ChamorroA: Proinflammatory cytokines and early neurological worsening in ischemic stroke.Stroke31(10), 2325–2329 (2000).
  • Vila N , CastilloJ, DávalosA, EsteveA, PlanasAM, ChamorroA: Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke.Stroke34(3), 671–675 (2003).
  • Smith CJ , EmsleyHC, GavinCMet al.: Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome.BMC Neurol.4, 2 (2004).
  • Qizilbash N , LewingtonSL, Lopez-ArrietaJM: Corticosteroids for acute ischaemic stroke.Cochrane Database Syst. Rev.2(2), CD000064 (2002).
  • Casas JP , ShahT, HingoraniAD, DaneshJ, PepysMB: C-reactive protein and coronary heart disease: a critical review.J. Intern. Med.264(4), 295–314 (2008).
  • Kuhlmann CR , LibrizziL, CloshenDet al.: Mechanisms of C-reactive protein-induced blood–brain barrier disruption.Stroke40(4), 1458-66 (2009).
  • Rost NS , WolfPA, KaseCSet al.: Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study.Stroke32(11), 2575–2579 (2001).
  • Montaner J , Fernandez-CadenasI, MolinaCAet al.: Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis.Stroke37(5), 1205–1210 (2006).
  • Arenillas JF , Alvarez-SabínJ, MolinaCAet al.: C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease.Stroke34(10), 2463–2468 (2003).
  • Purroy F , MontanerJ, MolinaCAet al.: C-reactive protein predicts further ischemic events in transient ischemic attack patients.Acta Neurol. Scand.115(1), 60–66 (2007).
  • Rosell A , Ortega-AznarA, Alvarez-SabánJet al.: Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke.Stroke37(6), 1399–1406 (2006).
  • Abilleira S , MontanerJ, MolinaCA, MonasterioJ, CastilloJ, Alvarez-SabínJ: Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage.J. Neurosurg.99(1), 65–70 (2003).
  • Montaner J , Alvarez-SabínJ, MolinaCet al.: Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment.Stroke32(8), 1759–1766 (2001).
  • Montaner J , Alvarez-SabínJ, MolinaCAet al.: Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke.Stroke32(12), 2762–2767 (2001).
  • Montaner J , MolinaCA, MonasterioJet al.: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.Circulation107(4), 598–603 (2003).
  • Ning M , FurieKL, KoroshetzWJet al.: Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.Neurology66(10), 1550–1555 (2006).
  • Castellanos M , SobrinoT, MillanMet al.: Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.Stroke38(6), 1855–1859 (2007).
  • Rosell A , Alvarez-SabínJ, ArenillasJFet al.: A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke.Stroke36(7), 1415–1420 (2005).
  • Alvarez-Sabín J , DelgadoP, AbilleiraSet al.: Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome.Stroke35(6), 1316–1322 (2004).
  • Rabuffetti M , ScioratiC, TarozzoG, ClementiE, ManfrediAA, BeltramoM: Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines.J. Neurosci.20(12), 4398–4404 (2000).
  • Cohen GM : Caspases: the executioners of apoptosis.Biochem. J.326(Pt 1), 1–16 (1997).
  • Bratton SB , MacFarlaneM, CainK, CohenGM: Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis.Exp. Cell Res.256(1), 27–33 (2000).
  • Broughton BR , ReutensDC, SobeyCG: Apoptotic mechanisms after cerebral ischemia.Stroke40(5), e331–e339 (2009).
  • Rosell A , CuadradoE, Alvarez-SabínJet al.: Caspase-3 is related to infarct growth after human ischemic stroke.Neurosci. Lett.430(1), 1–6 (2008).
  • Delgado P , CuadradoE, RosellAet al.: Fas system activation in perihematomal areas after spontaneous intracerebral hemorrhage.Stroke39(6), 1730–1734 (2008).
  • Rainer TH , WongLK, LamWet al.: Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke.Clin. Chem.49(4), 562–569 (2003).
  • Cherubini A , RuggieroC, PolidoriMC, MecocciP: Potential markers of oxidative stress in stroke.Free Radic. Biol. Med.39(7), 841–852 (2005).
  • Heistad DD , WakisakaY, MillerJ, ChuY, Pena-SilvaR: Novel aspects of oxidative stress in cardiovascular diseases.Circ. J.73(2), 201–207 (2009).
  • Alexandrova M , BochevP, MarkovaVet al.: Dynamics of free radical processes in acute ischemic stroke: influence on neurological status and outcome.J. Clin. Neurosci.11(5), 501–506 (2004).
  • Kelly PJ , MorrowJD, NingMet al.: Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the biomarker evaluation for antioxidant therapies in stroke (BEAT-stroke) study.Stroke39(1), 100–104 (2008).
  • Liu H , UnoM, KitazatoKTet al.: Peripheral oxidative biomarkers constitute a valuable indicator of the severity of oxidative brain damage in acute cerebral infarction.Brain Res.1025(1–2), 43–50 (2004).
  • Sinha MK , GazeDC, TippinsJR, CollinsonPO, KaskiJC: Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention.Circulation107(19), 2403–2405 (2003).
  • Gunduz A , MenteseA, TurediSet al.: Serum ischaemia-modified albumin increases in critical lower limb ischaemia.Emerg. Med. J.25(6), 351–353 (2008).
  • Gunduz A , TurediS, MenteseAet al.: Ischemia-modified albumin in the diagnosis of acute mesenteric ischemia: a preliminary study.Am. J. Emerg. Med.26(2), 202–205 (2008).
  • Mentese A , MenteseU, TurediSet al.: Effect of deep vein thrombosis on ischaemia-modified albumin levels.Emerg. Med. J.25(12), 811–814 (2008).
  • Abboud H , LabreucheJ, MeseguerEet al.: Ischemia-modified albumin in acute strokeCerebrovasc. Dis.23(2–3), 216–220 (2007).
  • Allard L , BurkhardPR, LescuyerPet al.: PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke.Clin. Chem.51(11), 2043–2051 (2005).
  • Tomitori H , UsuiT, SaekiNet al.: Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke.Stroke36(12), 2609–2613 (2005).
  • Allard L , TurckN, BurkhardPRet al.: Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke.Biomark. Insights2, 155–164 (2007).
  • Turck N , AllardL, WalterNet al.: GSTP1 and UFD1 as early blood biomarkers of acute stroke.Cerebrovasc. Dis.21, 125 (2006).
  • A classification and outline of cerebrovascular diseases. II. Stroke6, 564–616 (1975).
  • Kidwell CS , AlgerJR, Di Salle F et al.: Diffusion MRI in patients with transient ischemic attacks. Stroke30(6), 1174–1180 (1999).
  • Engelter ST , ProvenzaleJM, PetrellaJR, AlbertsMJ: Diffusion MR imaging and transient ischemic attacks.Stroke30(12), 2762–2763 (1999).
  • Albers GW , CaplanLR, EastonJDet al.: Transient ischemic attack – proposal for a new definition.N. Engl. J. Med.347(21), 1713–1716 (2002).
  • Hill MD : Diagnostic biomarkers for stroke: a stroke neurologist‘s perspective.Clin. Chem.51(11), 2001–2002 (2005).
  • Whiteley W , TsengMC, SandercockP: Blood biomarkers in the diagnosis of ischemic stroke: a systematic review.Stroke39(10), 2902–2909 (2008).
  • Noppe M , CrolsR, AndriesD, LowenthalA: Determination in human cerebrospinal fluid of glial fibrillary acidic protein, S-100 and myelin basic protein as indices of non-specific or specific central nervous tissue pathology.Clin. Chim. Acta155(2), 143–150 (1986).
  • Lamers KJ , van EngelenBG, GabreelsFJ, HommesOR, BormGF, WeversRA: Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol. Scand.92(3), 247–251 (1995).
  • Lamers KJ , VosP, VerbeekMM, RosmalenF, van GeelWJ, van EngelenBG: Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res. Bull.61(3), 261–264 (2003).
  • van Engelen BG , LamersKJ, GabreelsFJ, WeversRA, van GeelWJ, BormGF: Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin. Chem.38(6), 813–816 (1992).
  • Segal MB : The choroid plexuses and the barriers between the blood and the cerebrospinal fluid.Cell Mol. Neurobiol.20(2), 183–196 (2000).
  • Wardlaw JM , DoubalF, ArmitagePet al.: Lacunar stroke is associated with diffuse blood–brain barrier dysfunction.Ann. Neurol.65(2), 194–202 (2009).
  • Marchi N , RasmussenP, KapuralMet al.: Peripheral markers of brain damage and blood–brain barrier dysfunction.Restor. Neurol. Neurosci.21(3–4), 109–121 (2003).
  • Anderson RE , WinnerkvistA, HanssonLOet al.: Biochemical markers of cerebrospinal ischemia after repair of aneurysms of the descending and thoracoabdominal aorta.J. Cardiothorac. Vasc. Anesth.17(5), 598–603 (2003).
  • Marchi N , FazioV, CuculloLet al.: Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption.J. Neurosci.23(5), 1949–1955 (2003).
  • Engelter ST , ProvenzaleJM, PetrellaJR, DeLongDM, AlbertsMJ: Infarct volume on apparent diffusion coefficient maps correlates with length of stay and outcome after middle cerebral artery stroke.Cerebrovasc. Dis.15(3), 188–191 (2003).
  • Ay H , KoroshetzWJ, VangelMet al.: Conversion of ischemic brain tissue into infarction increases with age.Stroke36(12), 2632–2636 (2005).
  • Ay H , ArsavaEM, RosandJet al.: Severity of leukoaraiosis and susceptibility to infarct growth in acute stroke.Stroke39(5), 1409–1413 (2008).
  • Wu O , KoroshetzWJ, OstergaardLet al.: Predicting tissue outcome in acute human cerebral ischemia using combined diffusion- and perfusion-weighted MR imaging.Stroke32(4), 933–942 (2001).
  • Beaulieu C , de CrespignyA, TongDC, MoseleyME, AlbersGW, MarksMP: Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: evolution of lesion volume and correlation with clinical outcome. Ann. Neurol.46(4), 568–578 (1999).
  • Menezes NM , AyH, Wang ZhuMet al.: The real estate factor: quantifying the impact of infarct location on stroke severity. Stroke38(1), 194–197 (2007).
  • Thijs VN , LansbergMG, BeaulieuC, MarksMP, MoseleyME, AlbersGW: Is early ischemic lesion volume on diffusion-weighted imaging an independent predictor of stroke outcome? A multivariable analysis.Stroke31(11), 2597–2602 (2000).
  • Schiemanck SK , KwakkelG, PostMW, KappelleLJ, PrevoAJ: Predicting long-term independency in activities of daily living after middle cerebral artery stroke: does information from MRI have added predictive value compared with clinical information?Stroke37(4), 1050–1054 (2006).
  • Schiemanck SK , KwakkelG, PostMW, PrevoAJ: Predictive value of ischemic lesion volume assessed with magnetic resonance imaging for neurological deficits and functional outcome poststroke: a critical review of the literature.Neurorehabil. Neural Repair20(4), 492–502 (2006).
  • Lynch JR , BlessingR, WhiteWD, GrocottHP, NewmanMF, LaskowitzDT: Novel diagnostic test for acute stroke.Stroke35(1), 57–63 (2004).
  • Reynolds MA , KirchickHJ, DahlenJRet al.: Early biomarkers of stroke.Clin. Chem.49(10), 1733–1739 (2003).
  • Laskowitz DT , KasnerSE, SaverJ, RemmelKS, JauchEC; BRAIN Study Group: Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the biomarker rapid assessment in ischemic injury (BRAIN) study. Stroke40(1), 77–85 (2009).
  • Montaner J , Perea-GainzaM, DelgadoPet al.: Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers.Stroke39(8), 2280–2287 (2008).
  • Castellanos M , SerenaJ: Applicability of biomarkers in ischemic stroke.Cerebrovasc. Dis.24(Suppl. 1), 7–15 (2007).
  • Montaner J : Stroke biomarkers: can they help us to guide stroke thrombolysis?Timely Top. Med. Cardiovasc. Dis.11, E11 (2007).
  • Lynch JR , WangH, McGirtMJet al.: Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: Results of a pilot randomized clinical trial.Stroke36(9), 2024–2026 (2005).
  • Pettigrew LC , KasnerSE, GormanMet al.: Effect of arundic acid on serum S-100b in ischemic stroke.J. Neurol. Sci.251(1–2), 57–61 (2006).
  • Fisher M , CheungK, HowardG, WarachS: New pathways for evaluating potential acute stroke therapies.Int. J. Stroke1(2), 52–58 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.